Harnessing Myeloid Cells to Attack Cancer

The advent of immunotherapies is transforming cancer care. While early efforts have focused on enabling T cells to attack cancers, Myeloid Therapeutics is developing next-generation immunotherapies that use mRNA to train myeloid cells to attack cancer. We spoke to Daniel Getts, founder and CEO of Myeloid Therapeutics, about the limitations of existing immunotherapies, the role myeloid cells play in the immune system, and the benefits of the company’s therapeutic approach.